Earlier, Dr Glenn was the chief scientific officer and founder of IOMAI Corporation (now Intercell), an associate in international health at Johns Hopkins University’s School of Public Health and a clinical and basic research scientist at Walter Reed Army Institute of Research.
Mr Singhvi said: “Greg Glenn is a recognised innovator and authority on vaccines, vaccine delivery and adjuvants. He brings to Novavax considerable experience in the discovery, development and clinical evaluation of a wide variety of vaccines to prevent diseases such as pandemic influenza, tetanus, malaria, HIV and cancer.”
Dr Glenn said: “I am excited to join a very talented team and help them apply Novavax’s technology platform to the discovery and development of novel vaccines.
“The use of virus-like particles to mimic live viruses is a very promising approach to preventing the spread of infectious diseases. I look forward to supporting the development and application of this very promising approach to disease prevention.”